Ramucirumab - Eli Lilly

Drug Profile

Ramucirumab - Eli Lilly

Alternative Names: Anti-flk-1 monoclonal antibody - ImClone; Anti-KDR monoclonal antibody - ImClone; Anti-VEGFR 2 monoclonal antibody - ImClone; Cyramza; IMC-1121; IMC-1121-B; IMC-1C11 - ImClone; LY-3009806; Ramcilumab; ramsilmab; Ramsilomab; Ramsylmab; Ramsylumab; Sairamza; Silamza

Latest Information Update: 15 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dyax
  • Developer AstraZeneca; Dana-Farber Cancer Institute; Eli Lilly; Merck Sharp & Dohme; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Gastric cancer; Non-small cell lung cancer
  • Preregistration Liver cancer
  • Phase III Oesophageal cancer; Urogenital cancer
  • Phase II Biliary cancer; Carcinoid tumour; Solid tumours
  • No development reported Breast cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 30 Sep 2018 Preregistration for Liver cancer (Second-line therapy or greater) in Japan and European Union (IV)
  • 30 Jun 2018 Phase-II clinical trials in Oesophageal cancer (Refractory metastatic disease) in Germany (IV) (EudraCT2016-003850-33)
  • 02 Jun 2018 Additional safety and efficacy data from the phase III RANGE trial in Urogenital cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top